Insight Holdings Group, LLC sold $38.4M of HNGE (indirect holdings)

Insight Holdings Group, LLC sold 426,171 indirectly-held shares of Hinge Health, Inc. (HNGE) at an average of $90.21 ($90.17–$91.00, $38.45M total) across 12 trades over 2026-07-07 to 2026-07-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Insight Holdings Group, LLC
Published Jul 10, 2026, 1:17 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 10, 2026, 1:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HNGE
Neutral
medium confidence
Mentioned
$HNGE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HNGENeutralLow
01

Why it matters

A $38.45M open-market sale by a major owner can influence short-term sentiment, but the 10b5-1 plan suggests reduced informational content about near-term fundamentals.

02

Market read

Traders may monitor HNGE for any follow-on selling signals, but the 10b5-1 framing makes this more of a sentiment datapoint than a catalyst.

03

What to watch

The filing does not disclose the owner’s remaining economic exposure (e.g., options, derivatives, or other vehicles), so the market may over-interpret the '0 shares' headline.

Relevance 6/10Novelty 6/10Timing: filed after-hours on 2026-07-09, covering sales from 2026-07-07 to 2026-07-09

Background

The article is an SEC Form 4 insider transaction disclosure for Hinge Health, Inc., reported by a 10% owner via indirect holdings.

Company-level read

Ticker impact

$HNGENeutralMedium confidence
Context

Insight Holdings Group, LLC, a 10% owner, sold 426,171 HNGE shares in open-market trades for about $38.45M, leaving 0 shares.

Expected impact

Near-term sentiment impact likely limited; any price reaction may fade unless accompanied by other news.

Evidence & confidence

The filing is a primary Form 4 disclosure with transaction size and timing, but it explicitly references a pre-arranged 10b5-1 plan, which typically reduces interpretive signal about new information.

Market effects

No direct sector read-through; this is company-specific ownership liquidity rather than a sector catalyst.

None indicated.

None indicated.

Counterpoint

Because the trades were executed under a pre-arranged 10b5-1 plan, the sale may reflect scheduled diversification or liquidity needs rather than bearish expectations.

Key entities

  • Hinge Health, Inc.

    Subject of the Form 4 disclosure, ticker HNGE.

  • Insight Holdings Group, LLC

    Reporter of the Form 4, sold 426,171 shares across 12 trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HNGEHighAI 8/10

Needham raises Hinge Health stock price target on client growth

Needham raised its price target for Hinge Health (NYSE:HNGE) to $135 from $115, citing strong client growth and quarterly performance. The company reported 28% year-over-year client growth, 50% revenue increase, and 154% stock return over six months. Q3 revenue was $235 million, up 52% year-over-year, with EPS of $0.66 beating estimates. Wells Fargo also raised its target to $132, noting strong margins and revenue growth.

$HNGEHighAI 8/10

Hinge Health (HNGE) Q3 2026 Earnings Call Transcript

Hinge Health (HNGE) reported Q3 2026 revenue of $235M, up 52% YoY, with gross margin at 88% and operating income at $77M. The company highlighted growth in its MSK, Migraine, and GI care programs, with strong early results in Migraine care. President Jim Pursley announced his departure at year-end to spend more time with family but will join the board.